Brainsway Deep TMS was widely tested in leading institutions worldwide and was proven to be effective, as shown in the following instances.
In a wide multi-center study1, Brainsway Deep TMS depression treatment was tested for treating depression patients who previously used antidepressants without success. In this multi-center study, which included 230 patients, Brainsway Deep TMS generated significant improvement for depression patients. Following this study, the FDA cleared Brainsway Deep TMS for the treatment of depression patients who did not benefit from any number of previous medication treatments.
In another study, lasting 18 weeks 2, a significant decline was found in patients’ depressive symptoms after 4 weeks of Brainsway Deep TMS treatment, and was maintained throughout the study. The treatment was generally well tolerated and no adverse events were reported. According to the study results, Deep TMS continuation treatment can help maintain an anti-depressive effect for 18 weeks, following 4 weeks of acute treatment.
Brainsway Deep TMS depression treatment was also tested in a trial at McGill University in Canada3 Â for TRD (treatment resistant depression) patients. The patients’ response (indicating an improvement of at least 50% in depression symptoms) and remission (HDRS-21 scores, which rate depressive symptoms, lower than 10) rates were 70.6 and 41.2%, respectively. In this study, depression, anxiety ratings and quality of life scores significantly improved as well. The study showed that Deep TMS therapy improves depressive and anxiety symptoms in TRD patients. Furthermore, Deep TMS treatment was not associated with serious adverse events.
- Levkovitz Y. et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective, multi-center, randomized, controlled trial. World
Psychiatry 2015; Vol.14, 64-73.
- Harel EV, Rabany L, Deutsch L, Bloch Y, Zangen A, Levkovitz Y. H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder:
An 18-week continuation safety and feasibility study. World J Biol Psychiatry 2014;15(4):298-306
- Berlim MT, Van den Eynde F, Tovar-Perdomo S, Chachamovich E, Zangen A, Turecki G. Augmenting antidepressants with deep transcranial magnetic stimulation (DTMS)
in treatment-resistant major depression. World J Biol Psychiatry. 2014;15(7):570-578.